Opendata, web and dolomites

DesignerAntibiotics

Towards the prevention of aminoglycoside antibiotic-related deafness

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 DesignerAntibiotics project word cloud

Explore the words cloud of the DesignerAntibiotics project. It provides you a very rough idea of what is the project "DesignerAntibiotics" about.

drawback    threatening    intensive    clinical    publication    incidence    generation    incurred    dna    patients    diminish    patient    care    antibacterial    shown    22    hearing    distinction    vitro    economically    published    suffer    modify    urgent    journal    resistance    damage    biobank    life    acquisition    limits    group    potency    patented    billion    ototoxicity    profoundly    drug    annually    resistant    15    author    gt    despite    class    ucl    amounts    stanford    aminoglycosides    mitochondrial    maintaining    antimicrobials    1555a    investigation    murine    million    biology    caused    25    rare    london    genetics    molecular    impedes    ear    data    guided    first    exposed    100    chemically    university    bacteria    deaf    phd    aminoglycoside    antibiotics    children    compounds    treatment    cells    effect    mutation    masters    20    candidate    models    infections    78    inner    imperial    impairment    profound    infancy    neonatal    crystallography    human    annual    critically    die    structural    safer    language    irreversible    occurs    college   

Project "DesignerAntibiotics" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITY COLLEGE LONDON 

Organization address
address: GOWER STREET
city: LONDON
postcode: WC1E 6BT
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Total cost 251˙857 €
 EC max contribution 251˙857 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2015
 Funding Scheme MSCA-IF-GF
 Starting year 2017
 Duration (year-month-day) from 2017-02-13   to  2020-02-12

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITY COLLEGE LONDON UK (LONDON) coordinator 251˙857.00
2    BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY US (STANFORD) partner 0.00

Map

 Project objective

Aminoglycosides are critically important antimicrobials used in the treatment of life-threatening infections. A major drawback of usage is hearing loss caused by irreversible damage to the inner ear (ototoxicity). Ototoxicity occurs in ~20% of patients and ~100% of patients with the m.1555A>G mitochondrial DNA mutation. The largest EU patient group exposed to aminoglycosides are children in neonatal intensive care and the effect of hearing loss during infancy is particularly profound as it impedes language acquisition. Thus, there is an urgent need to develop safer aminoglycoside antibiotics. Ototoxicity limits usage despite the antibacterial potency and low incidence of drug resistance provided by this class of antibiotics. Economically, the annual EU cost incurred by drug resistant infections amounts to €1.5 billion, and the cost of hearing impairment is estimated to be €78 billion. Moreover, 25,000 EU patients die annually as a result of infections caused by resistant bacteria and 22.5 million suffer from hearing impairment, with 2 million profoundly deaf.

Stanford research recently published in the Journal of Clinical Investigation has shown that it is possible to chemically modify aminoglycosides to diminish ototoxicity while maintaining antibacterial activity. Through a novel collaboration between Stanford and University College London (UCL), the aim of this research is to use a results-guided drug design approach to develop the next generation of safer aminoglycoside antibiotics. For this work, the candidate will have access to 15 novel patented aminoglycoside compounds, crystallography data, murine in vitro and in vitro models of ototoxicity, and a rare biobank of cells from patients with the m.1555A>G mutation. This work will build upon the candidate’s Distinction Masters of Research structural biology experience at Imperial College London, and UCL PhD and recent first-author publication in Human Molecular Genetics related to aminoglycoside ototoxicity.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "DESIGNERANTIBIOTICS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "DESIGNERANTIBIOTICS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

CoCoNat (2019)

Coordination in constrained and natural distributed systems

Read More  

PaSION (2018)

A longitudinal assessment of treatment experience, symptoms and potential associations with biomarkers in cancer patients undergoing immune checkpoint inhibitor therapy

Read More  

GainGrain (2019)

Understanding genetic hubs in rice inflorescence architecture to increase grain yield

Read More